Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1477-9560
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies ; volume:11 ; number:1 ; day:20 ; month:9 ; year:2013 ; pages:1-10 ; date:12.2013
Thrombosis journal ; 11, Heft 1 (20.9.2013), 1-10, 12.2013
- Creator
-
Prins, Martin H.
Lensing, Anthonie WA
Bauersachs, Rupert
van Bellen, Bonno
Bounameaux, Henri
Brighton, Timothy A.
Cohen, Alexander T.
Davidson, Bruce L.
Decousus, Hervé
Raskob, Gary E.
Berkowitz, Scott D.
Wells, Philip S.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1477-9560-11-21
- URN
-
urn:nbn:de:101:1-2019063003030212645070
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Prins, Martin H.
- Lensing, Anthonie WA
- Bauersachs, Rupert
- van Bellen, Bonno
- Bounameaux, Henri
- Brighton, Timothy A.
- Cohen, Alexander T.
- Davidson, Bruce L.
- Decousus, Hervé
- Raskob, Gary E.
- Berkowitz, Scott D.
- Wells, Philip S.
- SpringerLink (Online service)
Other Objects (12)
Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism : a pooled analysis of the EINSTEIN-DVT and PE randomized studies
Erratum to: ‘Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program’
Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies
Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies
Five years, five indications: rivaroxaban for the treatment and prevention of thromboembolism
Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery
Rivaroxaban for Thromboembolism Prophylaxis in Patients with Nephrotic Syndrome: A Single-Arm, Prospective Study
Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism : a pooled analysis of the EINSTEIN-DVT and PE randomized studies
Erratum to: ‘Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program’
Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies
Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies
Five years, five indications: rivaroxaban for the treatment and prevention of thromboembolism
Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery
Rivaroxaban for Thromboembolism Prophylaxis in Patients with Nephrotic Syndrome: A Single-Arm, Prospective Study
Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism : a pooled analysis of the EINSTEIN-DVT and PE randomized studies
Erratum to: ‘Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program’
Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies
Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies
Five years, five indications: rivaroxaban for the treatment and prevention of thromboembolism
Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery